Nicholas Baxter - Apr 26, 2024 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Director
Signature
/Nicholas Baxter/
Stock symbol
LEXX
Transactions as of
Apr 26, 2024
Transactions value $
$0
Form type
4
Date filed
5/10/2024, 05:11 PM
Previous filing
Jul 25, 2023
Next filing
Jul 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LEXX common shares 11K Apr 26, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Award $0 +5K +14.29% $0.00 40K Apr 26, 2024 Common Shares 5K $2.36 Direct
holding LEXX Stock Options 1.5K Apr 26, 2024 Common Shares 1.5K $3.00 Direct F1
holding LEXX Stock Options 6.5K Apr 26, 2024 Common Shares 5K $3.00 Direct F2
holding LEXX Stock Options 8.4K Apr 26, 2024 Common Shares 1.9K $3.00 Direct F3
holding LEXX Stock Options 11.8K Apr 26, 2024 Common Shares 3.4K $3.39 Direct
holding LEXX Stock Options 30K Apr 26, 2024 Common Shares 18.2K $1.96 Direct
holding LEXX Stock Options 35K Apr 26, 2024 Common Shares 5K $0.87 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $5.31 pursuant to shareholder approval received May 9, 2023
F2 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
F3 Repriced from $6.23 pursuant to shareholder approval received May 9, 2023